---
title: 祝贺巨子生物港交所主板成功上市
titleEN: Congratulations to Giant Biogene Listed on the HKEX
hide: false
type: 新消费
typeEN: New Consumption
createDate: 2022-11-03T16:33:03.741Z
abstract: 北京时间11月4日，中国基于生物活性成分的专业皮肤护理产品行业的领军者巨子生物（股票代码：02367.HK）在港交所主板上市，成为“胶原蛋白第一股”。此前，2021年10月，巨子生物完成了自成立以来唯一一轮融资，高榕资本参与投资。
abstractEN: "On November 4, Giant Biogene (stock code: 02367.HK), a leader in
  China's professional skin care product industry based on bioactive
  ingredients, was listed on the main board of the HKEX, becoming the \"first
  collagen stock\". Previously, in October 2021, Giant Biogene completed the
  only round of financing since its establishment, and Gaorong Capital
  participated in the investment."
content: >-
  北京时间11月4日，中国基于生物活性成分的专业皮肤护理产品行业的领军者巨子生物（股票代码：02367.HK）在港交所主板上市，成为“胶原蛋白第一股”。此前，2021年10月，巨子生物完成了自成立以来唯一一轮融资，高榕资本参与投资。


  ![](/static/img/juziipo_22-11.jpg)


  巨子生物是中国重组胶原蛋白行业先行者及领军者，研发团队核心范代娣博士是胶原蛋白行业乃至中国生物医用材料领域的领军人物之一。经过多年积累，巨子生物建立了集生物技术、生物化学及生物工程等跨学科科研和多年行业专知为一体的合成生物学技术平台。巨子生物已先后研发出了33种不同类型的重组胶原蛋白并成功量产，此外还自主开发和生产稀有人参皂苷。


  截至上市前，巨子生物的专业皮肤护理产品及保健食品组合包含八大主要品牌的106项SKU，其中就包括了巨子生物的两大旗舰品牌可复美和可丽金。可丽金和可复美分别是2021年中国专业皮肤护理产品行业第三和第四畅销品牌（按零售额计）。


  2021年中国功效性护肤品的市场规模达到308亿元，巨子生物为2021年中国第二大专业皮肤护理产品公司，同时从2019年起连续三年一直是中国最大的胶原蛋白专业皮肤护理产品公司。


  聚焦研发力和产品力的同时，巨子生物维持了高质量的业绩增长。数据显示，2019年至2021年，公司收入分别为人民币9.57亿元、11.90亿元及15.52亿元，复合年均增长率约27.39%；截至2022年5月31日止五个月，收入和净利润分别达人民币7.23亿元和3.14亿元，盈利能力强劲。


  科技和创新是巨子生物的支点，也是撬动企业指数增长的杠杆。高榕资本合伙人韩锐表示，“巨子生物完全称得上是一家十年磨一剑的公司，公司在产品研发上的投入和创新能力让人惊叹。未来，相信在范教授的科研能力和严总的企业家精神带领下，巨子会持续创造独特的价值。”
contentEN: >-
  On November 4, Giant Biogene (stock code: 02367.HK), a leader in China's
  professional skin care product industry based on bioactive ingredients, was
  listed on the main board of the HKEX, becoming the "first collagen stock".
  Previously, in October 2021, Giant Biogene completed the only round of
  financing since its establishment, and Gaorong Capital participated in the
  investment.


  ![](/static/img/juziipo_22-11.jpg)


  Giant Biogene is the pioneer and leader of China's recombinant collagen industry. Dr. Fan Daidi, the core of the R&D team, is one of the leaders in the collagen industry and even in the field of biomedical materials in China. After years of accumulation, Giant Biogene has established a synthetic biology technology platform integrating interdisciplinary scientific research in biotechnology, biochemistry and bioengineering and years of industry expertise. Giant Biogene has successively developed 33 different types of recombinant collagen and successfully mass-produced them. In addition, it has independently developed and produced rare ginsenosides.


  Before listing, Giant Biogene's professional skin care products and health food portfolio included 106 SKUs of eight major brands, including Giant Biogene's two flagship brands, Kefumei and Collgene. Collgene and Kefumei are the third and fourth best-selling brands (in terms of retail sales) in China's professional skin care product industry in 2021, respectively.


  In 2021, the market size of China's functional skin care products will reach 30.8 billion yuan. Giant Biogene is the second largest professional skin care product company in China in 2021. At the same time, it has been the largest collagen professional skin care product company in China for three consecutive years since 2019 .


  While focusing on R&D and product capabilities, Giant Biogene has maintained high-quality performance growth. The data shows that from 2019 to 2021, the company's revenue is RMB 957 million, RMB 1.190 billion and RMB 1.552 billion respectively, with a compound annual growth rate of about 27.39%; Profit reached RMB 723 million and RMB 314 million respectively, showing strong profitability.
pic: /static/img/juziipo_22-11.jpg
highLight: false
---
